ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company has announced the appointment of Nplus1 Singer Advisory LLP (‘Singer Capital Markets’) as its joint broker with immediate effect.
ReNeuron is a leading, clinical-stage stem cell business with a primary objective to develop novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
Current Market Cap: £55 million
Life sciences is one of the core sector we cover, along with Technology, Healthcare, Industrials, Consumer and General Retail, Media, Support Services, Financials and Investment Funds. To learn more about our clients, click here.